More about

Hepatocellular Carcinoma

News
November 22, 2019
3 min read
Save

Highlights from The Liver Meeting: 6 reports on viral hepatitis

This year’s The Liver Meeting provided many exciting updates for viral hepatitis care ranging from steps toward eliminating hepatitis C to improving hepatitis B treatment options through data on hepatitis D.

News
November 15, 2019
2 min read
Save

Improving frailty in patients with cirrhosis listed for LT reduces mortality

BOSTON — Improvements in frailty among patients with cirrhosis awaiting liver transplantation lowered the risk for mortality regardless of baseline frailty and MELD-Na score, according to data presented at The Liver Meeting 2019.

News
November 13, 2019
3 min watch
Save

VIDEO: Blood-based panel detects early-stage liver cancer

VIDEO: Blood-based panel detects early-stage liver cancer

BOSTON — In this exclusive video from The Liver Meeting 2019, Naga P. Chalasani, MD, from the Indiana University School of Medicine, discusses the accuracy of combined methylated DNA and protein markers for early-stage detection of hepatocellular carcinoma.

News
November 13, 2019
2 min read
Save

‘Quest for better HDV therapy’: triple combination reduces RNA in most

BOSTON — Triple combination therapy with lonafarnib, ritonavir, and Lambda for chronic hepatitis D appeared safe and tolerable for up to 6 months in most patients and led to high rates of RNA decline, according to data presented at The Liver Meeting 2019.

News
November 11, 2019
1 min read
Save

FDA grants priority review, breakthrough therapy designation to Opdivo-Yervoy combination for HCC

The FDA granted the combination of nivolumab and ipilimumab priority review and breakthrough therapy designation for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib, according to a company-issued press release.

News
November 10, 2019
2 min read
Save

Cirrhosis-related financial burden impairs liver cancer surveillance

BOSTON — Researchers found that health care financial burden was common in patients with cirrhosis and may be associated with lower receipt of hepatocellular carcinoma surveillance, according to a presenter at The Liver Meeting 2019.

News
November 08, 2019
2 min read
Save

Albumin, liver stiffness after DAA therapy for HCV stratify liver cancer risk

Albumin levels and liver stiffness measurements taken during direct-acting antiviral therapy follow-up can stratify liver cancer risk among patients with hepatitis C and compensated advanced chronic liver disease, according to study results.

News
November 04, 2019
1 min read
Save

Namodenoson compassionate use program for HCC launches

Can-Fite BioPharma announced the initiation of a compassionate use program for Namodenoson to treat patients with hepatocellular carcinoma, according to a press release.

News
October 29, 2019
1 min read
Save

Tecentriq, Avastin combination improves survival in unresectable HCC

Combination treatment with Tecentriq and Avastin for unresectable hepatocellular carcinoma in patients without prior systemic therapy demonstrated clinically meaningful improvements in both overall and progression-free survival compared with Nexavar, according to a press release from Genentech.

News
October 24, 2019
2 min read
Save

National Liver Conference to cover ‘tsunami’ of new data on liver disease

SAN ANTONIO — The National Liver Congress will convene October 25th, providing a broad scientific program and exhibit of products and services important for all practitioners involved in the care of patients with liver disease.

View more